We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron (REGN) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Regeneron (REGN - Free Report) closed at $698.43 in the latest trading session, marking a +0.73% move from the prior day. The stock lagged the S&P 500's daily gain of 1.23%. At the same time, the Dow added 0.97%, and the tech-heavy Nasdaq gained 0.44%.
Prior to today's trading, shares of the biopharmaceutical company had gained 12.14% over the past month. This has outpaced the Medical sector's gain of 4.31% and the S&P 500's gain of 4.69% in that time.
Regeneron will be looking to display strength as it nears its next earnings release. On that day, Regeneron is projected to report earnings of $9.39 per share, which would represent a year-over-year decline of 5.06%. Meanwhile, our latest consensus estimate is calling for revenue of $2.98 billion, up 18% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $44.52 per share and revenue of $11.87 billion. These totals would mark changes of -40.37% and -26.14%, respectively, from last year.
Any recent changes to analyst estimates for Regeneron should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.08% lower. Regeneron is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, Regeneron is currently trading at a Forward P/E ratio of 15.57. For comparison, its industry has an average Forward P/E of 22.59, which means Regeneron is trading at a discount to the group.
We can also see that REGN currently has a PEG ratio of 1.2. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.2 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 160, which puts it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Regeneron (REGN) Gains But Lags Market: What You Should Know
Regeneron (REGN - Free Report) closed at $698.43 in the latest trading session, marking a +0.73% move from the prior day. The stock lagged the S&P 500's daily gain of 1.23%. At the same time, the Dow added 0.97%, and the tech-heavy Nasdaq gained 0.44%.
Prior to today's trading, shares of the biopharmaceutical company had gained 12.14% over the past month. This has outpaced the Medical sector's gain of 4.31% and the S&P 500's gain of 4.69% in that time.
Regeneron will be looking to display strength as it nears its next earnings release. On that day, Regeneron is projected to report earnings of $9.39 per share, which would represent a year-over-year decline of 5.06%. Meanwhile, our latest consensus estimate is calling for revenue of $2.98 billion, up 18% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $44.52 per share and revenue of $11.87 billion. These totals would mark changes of -40.37% and -26.14%, respectively, from last year.
Any recent changes to analyst estimates for Regeneron should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.08% lower. Regeneron is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, Regeneron is currently trading at a Forward P/E ratio of 15.57. For comparison, its industry has an average Forward P/E of 22.59, which means Regeneron is trading at a discount to the group.
We can also see that REGN currently has a PEG ratio of 1.2. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.2 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 160, which puts it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.